Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2022* -- Results Q4 2021 -- -0.27 --
02/24/2022* 16:30 EST Earnings Call Q4 2021 -- -- --
11/03/2021 -- Results Q3 2021 -0.39 -0.33 -18.18%
11/03/2021 08:30 EST Earnings Call Q3 2021 -- -- --
08/05/2021 -- Results Q2 2021 -0.37 -0.36 -1.57%
08/05/2021 16:30 EST Earnings Call Q2 2021 -- -- --
05/06/2021 -- Results Q1 2021 -0.40 -0.37 -6.95%
05/06/2021 17:00 EST Earnings Call Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/24/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2021
Beat/Miss Upgrade
Return Since -49.16%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.
URL http://www.auriniapharma.com
Investor Relations URL https://ir.auriniapharma.com
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 24, 2022
Last Earnings Release Nov. 03, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-32.14%
-14.98%
115.7%
50.55%
197.1%
-31.74%
65.37%
-32.44%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.67%
19.24%
-13.50%
7.72%
-12.91%
27.86%
0.39%
2.89%
0.70%
-44.04%
-68.72%
-60.09%
-83.95%
-24.91%
3.66%
32.47%
-27.18%
47.27%
-31.65%
-37.82%
-81.28%
-95.69%
-49.88%
-74.05%
-19.27%
-59.29%
-4.23%
-63.31%
123.4%
107.8%
17.32%
103.1%
-15.24%
As of January 26, 2022.

Profile

Edit
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.
URL http://www.auriniapharma.com
Investor Relations URL https://ir.auriniapharma.com
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 24, 2022
Last Earnings Release Nov. 03, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
F000016ZDA 761.00 USD 7.61%
F000015ZK5 599.00 USD 5.99%
F000018445 507440.0 USD 5.07%
FHYCPX 461514.0 USD 4.62%
BBP 335818.0 USD 1.99%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits AUPH Tweets